Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05422534 · ClinicalTrials.gov registry record · Phase 3
CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease
A Phase 3 study of End Stage Renal Disease, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 156
- Enrollment target
- 2
- Study locations
NCT05422534 is a Phase 3 study of End Stage Renal Disease that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 156 participants, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05422534, a Phase 3 study of End Stage Renal Disease, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 156 participants
- Enrollment target
- 2
- Study locations
Study Summary
Frailty and sarcopenia are modifiable risk factors for morbidity and mortality in patients with ESRD. Exercise is the recommended intervention to prevent frailty and sarcopenia, however, many clinical trials have shown limited clinical improvement in muscle mass and physical function. We propose that mitochondrial dysfunction is one of the deterrents to the effectiveness of the exercise. We plan to evaluate the additive effect of HIIT and CoQ10, a mitochondrial-targeted therapy, on mitochondrial function and physical performance. Understanding the interplay among CoQ10, exercise, and mitochondrial function will identify novel mechanisms to improve the efficiency of exercise. This will also serve to prevent frailty, sarcopenia, and muscle dysfunction in patients with ESRD.
Conditions Studied
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT CoQ10
- BEHAVIORAL HB-HIIT
- BEHAVIORAL Observational
Study Locations (2)
California
- University of California Davis Health - Sacramento
Tennessee
- Vanderbilt University Medical Center-GCRC - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2027-10-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05422534
The ClinicalTrials.gov registry entry for NCT05422534 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (81% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with End Stage Renal Disease appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT05422534 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05422534 about?
NCT05422534 is a clinical study titled "CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease". Frailty and sarcopenia are modifiable risk factors for morbidity and mortality in patients with ESRD. Exercise is the recommended intervention to prevent frailty and sarcopenia, however, many clinical trials have shown limited clinical improvement in muscle mass and physical function. We propose tha...
What is the current status of trial NCT05422534?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 156 participants. The study started on 2023-06-01. Estimated completion is 2027-10-01.
What conditions does trial NCT05422534 study?
This clinical trial studies the following conditions: End Stage Renal Disease.
What interventions are being tested in trial NCT05422534?
The interventions under investigation include: Placebo (DRUG), CoQ10 (DIETARY_SUPPLEMENT), HB-HIIT (BEHAVIORAL), Observational (BEHAVIORAL).
Who is sponsoring clinical trial NCT05422534?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05422534 being conducted?
This trial has 2 study locations across California, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
RECRUITING · Phase 3
-
Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis
COMPLETED · Phase 3
-
A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis
COMPLETED · Phase 3
-
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
COMPLETED · Phase 3
-
Prevention of Kidney Transplant Rejection
COMPLETED · Phase 3
-
An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.